Mesoblast (ASX:MSB) Is Up 8.7% After Strong Ryoncil Debut And FDA BLA Milestone - Has The Bull Case Changed?

• In July 2026, Mesoblast reported that the FDA had accepted its Biologics License Application for rexlemestrocel‑L in preventing life‑threatening gastrointestinal bleeding in end‑stage heart failure patients with LVADs, while the therapy continued to benefit from Orphan Drug and RMAT designations under newly clarified, more flexible FDA guidance for rare diseases.
• Separately, Mesoblast disclosed record Ryoncil net revenue of US$36,000,000 for the quarter and US$115,000,000 for its first full year of sales, supported by broad U.S. pediatric uptake and a new five‑year financing facility aimed at advancing label extensions and its wider cell therapy pipeline.
• We’ll now examine how Ryoncil’s stronger‑than‑expected first full year of revenue could influence Mesoblast’s existing investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Mesoblast Investment Narrative Recap

To own Mesoblast, you need to believe that Ryoncil can scale beyond a niche pediatric product while the rexlemestrocel L pipeline converts into approved, revenue generating therapies. In that context, the FDA’s acceptance of the rexlemestrocel L BLA and stronger Ryoncil revenue sharpen the near term catalyst around regulatory decisions, but the core risk is still whether sales and trial outcomes can support the company’s cash needs without heavier dilution.

The most relevant recent announcement here is Ryoncil’s first full year net revenue of US$115,000,000, well above its early run rate. That progress directly touches the previous concern that Ryoncil’s launch might stall and leave Mesoblast heavily cash burning. Instead, broader U.S. pediatric uptake and the new five year financing facility now intersect with the rexlemestrocel L BLA as twin catalysts that could reshape how investors weigh regulatory versus commercial execution risks.

Yet despite the progress, investors should be aware that dependence on expanding beyond a narrow pediatric niche still leaves Mesoblast exposed to ...

Read the full narrative on Mesoblast (it's free!)

Mesoblast's narrative projects $485.4 million revenue and $222.1 million earnings by 2029. This requires 204.5% yearly revenue growth and a $324.2 million earnings increase from $-102.1 million today.

Uncover how Mesoblast's forecasts yield a A$3.83 fair value, a 71% upside to its current price.

Exploring Other Perspectives

Before this news, the most pessimistic analysts were assuming revenue might reach about US$291,000,000 by 2029 and still questioned whether rexlemestrocel L’s trials would meaningfully broaden Mesoblast’s market, so you should recognize that views on future upside can differ sharply and may shift again as this new data is digested.

Explore 10 other fair value estimates on Mesoblast - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Mesoblast research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Mesoblast research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 6 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 8 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com